Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries.
Malaty IA, Martinez-Martin P, Chaudhuri KR, Odin P, Skorvanek M, Jimenez-Shahed J, Soileau MJ, Lindvall S, Domingos J, Jones S, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Onuk K, Bergmann L, Femia S, Lee MY, Wright J, Antonini A. Malaty IA, et al. Among authors: bergmann l. BMC Neurol. 2022 Jan 24;22(1):35. doi: 10.1186/s12883-022-02560-1. BMC Neurol. 2022. PMID: 35073872 Free PMC article.
Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries.
Antonini A, Pahwa R, Odin P, Henriksen T, Soileau MJ, Rodriguez-Cruz R, Isaacson SH, Merola A, Lindvall S, Domingos J, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Parra JC, Kukreja PK, Onuk K, Bergmann L, Pike J, Ray Chaudhuri K. Antonini A, et al. Among authors: bergmann l. Neurol Ther. 2022 Mar;11(1):303-318. doi: 10.1007/s40120-021-00313-9. Epub 2022 Jan 11. Neurol Ther. 2022. PMID: 35015215 Free PMC article.
Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population.
Antonini A, Marano P, Gusmaroli G, Modugno N, Pacchetti C, Sensi M, Melzi G, Bergmann L, Zibetti M, Lopiano L. Antonini A, et al. Among authors: bergmann l. Neurol Sci. 2020 Oct;41(10):2929-2937. doi: 10.1007/s10072-020-04401-w. Epub 2020 Apr 28. Neurol Sci. 2020. PMID: 32342325 Free PMC article.
Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: Analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS).
Kovács N, Szász J, Vela-Desojo L, Svenningsson P, Femia S, Parra JC, Sanchez-Soliño O, Bergmann L, Gurevich T, Fasano A. Kovács N, et al. Among authors: bergmann l. Parkinsonism Relat Disord. 2022 Dec;105:139-144. doi: 10.1016/j.parkreldis.2022.08.002. Epub 2022 Aug 17. Parkinsonism Relat Disord. 2022. PMID: 36008198 Free article.
Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P; GLORIA study co-investigators. Antonini A, et al. Among authors: bergmann l. Parkinsonism Relat Disord. 2017 Dec;45:13-20. doi: 10.1016/j.parkreldis.2017.09.018. Epub 2017 Sep 22. Parkinsonism Relat Disord. 2017. PMID: 29037498 Free article.
478 results